BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...Stanford University scientists found a unique anti-SARS-CoV-2 IgG...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

Abstracts at SITC and ASH are providing more data points on the efficacy of CD47 inhibitors, and the evidence suggests the target may hold promise in solid as well as liquid tumors. Known as a...
BioCentury | Nov 7, 2020
Emerging Company Profile

IgGenix: antibody engineering for food allergies

...for allergen binding. “IgE is the rarest of antibody classes. It’s orders of magnitude lower than IgG...
...but it uses a different antibody starting point than IgGenix. The big biotech is developing IgG...
...in Phase I. According to Croote, working from IgE antibodies has an advantage over using an IgG...
BioCentury | Oct 27, 2020
Distillery Therapeutics

UCSF team develops trivalent binder of SARS-CoV-2 spike for COVID-19

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus A UCSF team led by Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) founder Jim Wells has developed a trivalent immunoglobulin variable heavy domain-based inhibitor of the ACE2-SARS-CoV-2 S interaction that could treat COVID-19 infection....
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

Moderna won’t enforce COVID-19 IP during pandemicModerna Inc. (NASDAQ:MRNA) said on Thursday it will not enforce its COVID-19 related patents against vaccine developers addressing SARS-CoV2 while the pandemic continues. It added that it is willing...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
Items per page:
1 - 10 of 3780